Karyopharm Therapeutics Revenue, Profits - KPTI Quarterly Income Statement

Add to My Stocks
$18.49 $0.08 (0.43%) KPTI stock closing price Sep 19, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking Karyopharm Therapeutics stock price alone is not sufficient. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. The income statement for KPTI which shows a YOY revenue growth of 98.9% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The Karyopharm Therapeutics profit and loss statement for 2018 Q2 shows a net profit of $-33.66M. Profits for last year was $-38.46M. Apart from this an investor should also check Karyopharm Therapeutics assets and Karyopharm Therapeutics free cash flow.

View and download details of revenue and profits for Karyopharm Therapeutics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Karyopharm Therapeutics Revenues or Net Sales
19.89M10M1.53M-------
Cost Of Goods Sold (COGS)----------
Karyopharm Therapeutics Gross Profit
19.89M10M1.54M-------
Research & Development Expense44.73M41.32M34.84M25.23M23.12M24.08M20.68M19.89M24.57M21.79M
Selling General & Admin Expense9.49M7.62M6.17M5.81M6.63M6.26M6.55M5.89M5.95M5.55M
Income Before Depreciation Depletion Amortization-34.33M-38.94M-39.46M-31.05M-29.75M-30.27M-27.18M-25.74M-30.47M-27.34M
Depreciation Depletion Amortization----------
Non Operating Income----------
Interest Expense----------
Karyopharm Therapeutics Pretax Income
-33.67M-38.44M-39.05M-30.62M-29.36M-29.89M-26.81M-25.42M-30.15M-27.05M
Provision for Income Taxes-0.02M---------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-33.66M-38.46M-39.04M-30.64M-29.39M-29.92M-26.94M-25.43M-30.16M-27.06M
Extraordinary Items & Discontinued Operations----------
Karyopharm Therapeutics Profit/ Loss (Net Income)
-33.66M-38.46M-39.04M-30.64M-29.39M-29.92M-26.94M-25.43M-30.16M-27.06M
Average Shares used to compute Diluted EPS56.09M49.6M48.65M47.14M45.83M41.9M41.38M36.82M35.96M35.88M
Average Shares used to compute Basic EPS56.09M49.6M48.65M47.14M45.83M41.9M41.38M36.82M35.96M35.88M
Income Before Nonrecurring Items-33.66M-38.46M-39.04M-30.64M-29.39M-29.92M-26.94M-25.43M-30.16M-27.06M
Income from Nonrecurring Items----------
Karyopharm Therapeutics Earnings Per Share Basic Net
-0.60-0.78-0.80-0.65-0.64-0.71-0.65-0.69-0.84-0.75
Karyopharm Therapeutics Earnings Per Share Diluted Net
-0.60-0.78-0.80-0.65-0.64-0.71-0.65-0.69-0.84-0.75
EPS Diluted Before Nonrecurring Items-0.60-0.78-0.80-0.65-0.64-0.71-0.65-0.69-0.84-0.75
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Karyopharm Therapeutics stock analysis are:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that KPTI stock has a topline or revenue of $19.89M for 2018 Q2 as per this Karyopharm Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-33.66M for KPTI stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The KPTI financials along with Karyopharm Therapeutics historical stock prices provide a lot of details about the firm.

Karyopharm Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
33.01
Dividend Yield
0%